Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases

Research output: Contribution to journalArticle

80 Scopus citations

Abstract

BACKGROUND. In patients with bone pain due to metastatic disease, intravenous systemic radioisotope therapy may be a useful adjunct to other methods for palliating pain. METHODS. Various studies have been performed utilizing a short-lived radioisotope conjugated to a tetraphosphonate (samarium 153 lexidronam) both as an open label and as a double blinded, placebo-controlled study. Patients with varying tumor types including those of the prostate, breast, lung, and other sites were studied. Two dose levels were used (0.5 millicuries (mCi)/kg and 1.0 mCi/kg) with patients monitored for 16 weeks for efficacy (pain scores, opiod analgesic score, and quality of life) parameters and adverse events. RESULTS. All 3 studies showed that at the 1.0 mCi/kg dose level statistically significant improvement over placebo was observed by 4 weeks with relief of pain noted in many patients by 1 week. The only significant adverse event was transient myelosuppression with a nadir at 4-6 weeks and recovery by 8 weeks. Less than 10% of patients had National Cancer Institute Common Toxicity criteria Grade III/IV bone marrow toxicity recorded. CONCLUSIONS. Systemic metabolic radiotherapy with samarium 153 lexidronam appears to be a safe and efficacious method for treating patients with bone pain. The shorter radioisotope half-life allows for a high dose rate to be delivered over a short period, which may have certain biologic benefits. (C) 2000 American Cancer Society.

Original languageEnglish (US)
Pages (from-to)2934-2939
Number of pages6
JournalCancer
Volume88
Issue number12 SUPPL.
DOIs
StatePublished - Jun 15 2000

Keywords

  • Bone pain
  • Metastatic cancer
  • Samarium 153 lexidronam
  • Systemic radioisotope therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases'. Together they form a unique fingerprint.

  • Cite this